2016 American Transplant Congress
Adding an Antimetabolite to a Calcineurin-Inhibitor-Based Immunosuppression Regimen Leads to Improved Native Renal Function After Liver Transplantation.
Surgery, University of Wisconsin, Madison, WI.
Background: Nephrotoxic side effects of calcineurin inhibitors (CNI) have been well established. The addition of anti-metabolites (AM) to CNI-based immunosuppression (IS) regimens has been proposed…2016 American Transplant Congress
Liver Transplantation for Propionic Acidemia: A Review of the United States Scientific Registry for Transplant Recipients (SRTR) and Non-US Case Series.
Surgery, Childrens Hospital of Pgh, Pittsburgh.
Background: A fifth of all pediatric liver transplants in the US are performed for metabolic disease. Propionic acidemia, an autosomal recessive branched chain organic acidemia…2016 American Transplant Congress
Long-Term Outcomes After Pediatric Liver Transplantation for Malignant Liver Tumors: Effects of Era and Age.
Background: Hepatoblastoma (HB), hepatocellular carcinoma (HCC), along with hemangioendothelioma, hemangiosarcoma, and angiosarcoma (HHA) are rare tumors in children that are treated with orthotopic liver transplantation…2016 American Transplant Congress
Acute Kidney Injury After Liver Transplantation Is Set in Motion Early After Reperfusion of the Liver Graft: A Prospective Cohort Study.
Objective: Determine creatinine changes during liver transplantation and risk factors for acute kidney injury (AKI) in a prospective cohort study (NCT01333319).Background Data: AKI, a major…2016 American Transplant Congress
Normothermic Ex Vivo Liver Perfusion (NEVLP) Using Steen Solution as Preservation Technique for Liver Transplantation-First Clinical Results.
Surgery, Toronto General Hospital, Toronto, Canada.
The European trial investigating NEVLP as preservation technique for liver transplantation uses Gelafusine, a non-FDA approved bovine derived gelatin-based perfusion solution. In contrast, we report…2016 American Transplant Congress
A Sustained Viral Response Achieved with Sofosbuvir/Ledipasvir May Increase the Incidence of Acute Cellular Rejection Post Liver Transplantation.
Transplant Surgery, New York University Langone Medical Center, New York, NY.
Acute cellular rejection following liver transplantation has decreased in incidence with the use of potent immunosuppressive agents, affecting less than 25 percent of liver transplantation…2016 American Transplant Congress
Selection of Patients with Solitary Lesion of Hepatocellular Cancer for Liver Transplantation.
Milan criteria are considered as benchmark for selection of patients with hepatocellular cancer (HCC) for liver transplantation. The aim of this study was to evaluate…2016 American Transplant Congress
A Novel Inflammation-Targeting Tacrolimus Hydrogel for Liver Transplantation.
Background:Immunosuppressant have played a critical role for improving graft survival after liver transplantation (LT). While long-term systemic use of immunosuppressant such as tacrolimus (FK506) is…2016 American Transplant Congress
Same Policy, Different Impact: Center and Regional Effects of SHARE 35 Liver Allocation.
Introduction: Early studies of national data suggest that Share-35 implementation was associated with more liver transplants, fewer discards, and lower waitlist mortality, without worsening of…2016 American Transplant Congress
Increased Utilization of High Risk Deceased Donors with Share 35 Does Not Affect Outcomes in Liver Transplantation.
Background: Demand for livers from deceased donors exceeds supply after Share 35 in June 2013. This leads liver transplant centers to consider high risk deceased…
- « Previous Page
- 1
- …
- 148
- 149
- 150
- 151
- 152
- …
- 180
- Next Page »